Ertugliflozin
Ertugliflozin (trade name Steglatro) is a drug for the treatment of type 2 diabetes. In the United States, it was approved by the Food and Drug Administration for use as a monotherapy and as a fixed dose combination with either sitagliptin or with metformin. In Europe, it was approved in March 2018, for use as a monotherapy or combination therapy. In September 2020, The New England Journal of Medicine reported that ertugliflozin was shown to be essentially non-inferior to placebo.
C22H25ClO7Ertugliflozin/metforminErtugliflozin/sitagliptinErtugliflozin L-pyroglutamic acidErtugliflozin L-pyroglutamic acid, sitagliptin phosphate monohydrateErtugliflozin L-pyroglutamic acid/metformin hydrochlorideErtugliflozin L-pyroglutamic acid/sitagliptinErtugliflozin L-pyroglutamic acid/sitagliptin phosphateErtugliflozin L-pyroglutamic acid/sitagliptin phosphate monohydrateErtugliflozin l-pyroglutamic acid/metformin hydrochlorideErtugliflozin l-pyroglutamic acid/sitagliptin phosphate monohydrateMetformin/ertugliflozinSeglurometSteglatroSteglujan
Wikipage redirect
ATC code A10C22H25ClO7Ertugliflozin/metforminErtugliflozin/sitagliptinErtugliflozin L-pyroglutamic acidErtugliflozin L-pyroglutamic acid, sitagliptin phosphate monohydrateErtugliflozin L-pyroglutamic acid/metformin hydrochlorideErtugliflozin L-pyroglutamic acid/sitagliptinErtugliflozin L-pyroglutamic acid/sitagliptin phosphateErtugliflozin L-pyroglutamic acid/sitagliptin phosphate monohydrateErtugliflozin l-pyroglutamic acid/metformin hydrochlorideErtugliflozin l-pyroglutamic acid/sitagliptin phosphate monohydrateMetformin/ertugliflozinSGLT2 inhibitorSeglurometSteglatroSteglujan
Link from a Wikipage to another Wikipage
primaryTopic
Ertugliflozin
Ertugliflozin (trade name Steglatro) is a drug for the treatment of type 2 diabetes. In the United States, it was approved by the Food and Drug Administration for use as a monotherapy and as a fixed dose combination with either sitagliptin or with metformin. In Europe, it was approved in March 2018, for use as a monotherapy or combination therapy. In September 2020, The New England Journal of Medicine reported that ertugliflozin was shown to be essentially non-inferior to placebo.
has abstract
Ertugliflozin (trade name Steg ...... ptin is marketed as Steglujan.
@en
alternative name
Steglatro
@en
CAS number
1210344-57-2
DrugBank
FDA UNII code
6C282481IP
PubChem
Link from a Wikipage to an external page
Wikipage page ID
56,137,583
page length (characters) of wiki page
Wikipage revision ID
997,256,434
Link from a Wikipage to another Wikipage
ATC prefix
A10
@en
ATC suffix
BK04
@en
bioavailability
~100%
@en
CAS number
ChemSpiderID
26,340,533
DrugBank
DB11827
@en
elimination half-life
excretion
index2 label
as salt
@en
IUPAC name
KEGG
D10313
@en
D11043
@en
legal CA
Rx-only
@en
legal EU
Rx-only
@en
legal UK
POM
@en
legal US
Rx-only
@en
metabolites
Glucuronides
@en
pregnancy AU
D
@en
pregnancy US
N
@en
protein bound
PubChem
44,814,423
routes of administration
SMILES
CCOc1cccCc2cc[C@@]34[C@@H]O
@en
StdInChIKey
MCIACXAZCBVDEE-CUUWFGFTSA-N
@en
synonyms
PF-04971729, ertugliflozin l-pyroglutamic acid
@en
tradename
Steglatro
@en
wikiPageUsesTemplate
comment
Ertugliflozin (trade name Steg ...... ially non-inferior to placebo.
@en
label
Ertugliflozin
@en